Acrivon Therapeutics Inc (NASDAQ: ACRV) kicked off on Monday, down -6.91% from the previous trading day, before settling in for the closing price of $2.46. Over the past 52 weeks, ACRV has traded in a range of $1.05-$8.00.
A company in the Healthcare sector has dropped its sales by -74.96% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 14.36%. With a float of $22.27 million, this company’s outstanding shares have now reached $31.55 million.
Acrivon Therapeutics Inc (ACRV) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Acrivon Therapeutics Inc is 29.43%, while institutional ownership is 48.08%. The most recent insider transaction that took place on Apr 30 ’25, was worth 617,412. In this transaction 10% Owner of this company sold 437,881 shares at a rate of $1.41, taking the stock ownership to the 3,403,025 shares. Before that another transaction happened on May 01 ’25, when Company’s 10% Owner sold 298,886 for $1.34, making the entire transaction worth $400,507. This insider now owns 3,104,139 shares in total.
Acrivon Therapeutics Inc (ACRV) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.54 earnings per share (EPS), higher than consensus estimate (set at -0.7) by 0.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.86% during the next five years compared to -74.96% drop over the previous five years of trading.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Trading Performance Indicators
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.13, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -2.01 in one year’s time.
Technical Analysis of Acrivon Therapeutics Inc (ACRV)
Let’s dig in a bit further. During the last 5-days, its volume was 0.39 million. That was inferior than the volume of 0.43 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 54.76%.
During the past 100 days, Acrivon Therapeutics Inc’s (ACRV) raw stochastic average was set at 70.27%, which indicates a significant increase from 34.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.19 in the past 14 days, which was higher than the 0.16 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.28, while its 200-day Moving Average is $1.75. However, in the short run, Acrivon Therapeutics Inc’s stock first resistance to watch stands at $2.44. Second resistance stands at $2.58. The third major resistance level sits at $2.66. If the price goes on to break the first support level at $2.21, it is likely to go to the next support level at $2.13. Assuming the price breaks the second support level, the third support level stands at $1.98.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Key Stats
The company with the Market Capitalisation of 72.26 million has total of 31,555K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -80,560 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -18,230 K.
